Physician profile
Ashley Fultz
NPI 1457694960
$3,183.69
in general payments reported to CMS, 2019-2025
32 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $801 · 2023: $556 · 2024: $645 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $741.50 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $616.89 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.64 | 2021-2025 | Xifaxan |
| Pfizer INC. | $202.64 | 2021-2025 | |
| Exact Sciences Corporation | $114.88 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $106.99 | 2022-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $84.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.22 | 2021-2023 | Trintellix |
| Abbott Laboratories | $75.79 | 2022-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $71.98 | 2021-2024 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $66.68 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $65.92 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.32 | 2021-2022 | |
| Lilly USA, LLC | $59.16 | 2021-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $58.32 | 2023-2025 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $58.13 | 2021 | |
| Astellas Pharma US INC | $51.45 | 2021 | |
| Lundbeck LLC | $50.14 | 2023-2025 | Rexulti |
| Dexcom, INC. | $46.23 | 2021-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.46 | 2022 | |
| Glaxosmithkline, LLC. | $28.72 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $25.91 | 2025 | Voquezna |
| Amarin Pharma, INC. | $23.54 | 2021 | |
| Mylan Specialty L.P. | $21.72 | 2024 | Yupelri |
| Ardelyx, INC. | $20.12 | 2025 | Ibsrela |
| Seqirus USA INC | $19.65 | 2021 | |
| Merck Sharp & Dohme LLC | $16.52 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.49 | 2025 | Caplyta |
| Philips North America LLC | $16.23 | 2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2023 | |
| Amgen INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Fultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.